Cytosorbents Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 09/30/24 | FY 06/30/24 | FY 03/31/24 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $37.1M | $35.6M | — | — | — |
| Cost of revenue | $10.6M | $10.7M | — | — | — |
| Gross profit | $26.5M | $24.9M | — | — | — |
| Selling, general & administrative | $35.6M | $33.7M | — | — | — |
| Operating expenses | $41.2M | $41.3M | — | — | — |
| Operating income | -$14.7M | -$16.5M | — | — | — |
| Pretax income | -$8.6M | -$22.4M | — | — | — |
| Income tax expense | -$401,000 | -$1.7M | — | — | — |
| Net income | -$8.2M | -$20.7M | — | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $6.2M | $3.3M | — | — | — |
| Current assets | $20.6M | $21.6M | $16.6M | $22.0M | $20.0M |
| Total assets | $44.2M | $47.4M | $47.8M | $53.4M | $47.1M |
| Current liabilities | $9.7M | $9.8M | $8.3M | $9.6M | $12.7M |
| Total liabilities | $38.3M | $36.3M | $34.7M | $36.0M | $27.4M |
| Stockholders' equity | $5.9M | $11.1M | $13.1M | $17.4M | $19.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.4M | -$14.4M | — | — | — |
| Depreciation and amortization | $1.2M | $1.3M | — | — | — |
| Stock-based compensation | $2.8M | $3.8M | — | — | — |
| Capital expenditure | $164,000 | $284,000 | — | — | — |
| Free cash flow | -$12.5M | -$14.7M | — | — | — |
| Impairments | $104,000 | $333,735 | — | — | — |
Shares outstanding 62.8M · Free float 84.1%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.